Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bismuth cation (Bi3+) is the trivalent, positively charged ion of the element bismuth. It serves as the active moiety in several medicinal compounds, most notably in gastrointestinal agents such as bismuth subsalicylate and other bismuth salts. Bismuth cations exhibit antimicrobial and bactericidal properties by interfering with bacterial adhesion to mucosal surfaces and disrupting microbial cell walls. They also have anti-inflammatory effects when present as part of salicylate-containing compounds. Bismuth-based drugs are primarily used for symptomatic relief of gastrointestinal disorders including diarrhea, heartburn, indigestion, and upset stomach. Additionally, certain formulations are used in combination therapies for *Helicobacter pylori* eradication in peptic ulcer disease[1][4][5][8]. The precise mechanism of action is not fully understood but involves both direct antimicrobial activity and modulation of intestinal secretions[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bismuth cation.